<DOC>
	<DOCNO>NCT02048709</DOCNO>
	<brief_summary>This open-label Phase I study evaluate safety , tolerability , pharmacokinetics escalate oral dos GDC-0919 , investigational agent intend inhibit indoleamine 2,3-dioxygenase 1 ( IDO1 ) enzyme help human immune system attack solid tumor cell effectively .</brief_summary>
	<brief_title>Indoleamine 2,3-Dioxygenase ( IDO ) Inhibitor Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically confirm solid tumor relapsed/refractory standard therapy approve curative therapy exist Age &gt; = 18 Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Life expectancy &gt; = 12 week Adequate hematologic organ function initiation GDC0919 For patient : Accessible lesion amenable pair fresh tumor biopsy Some prior cancer immunotherapy Untreated brain metastasis Active history autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>